menu
    • menu
    [{"orgOrder":0,"company":"Icosavax","sponsor":"Bill & Melinda Gates Foundation and Open Philanthropy","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"IVX-411","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Icosavax","amount2":0.02,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.02,"dosageForm":"","sponsorNew":"Icosavax \/ Bill & Melinda Gates Foundation and Open Philanthropy","highestDevelopmentStatusID":"4","companyTruncated":"Icosavax \/ Bill & Melinda Gates Foundation and Open Philanthropy"},{"orgOrder":0,"company":"Icosavax","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2021","type":"Series B Financing","leadProduct":"Stabilized prefusion F antigen","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Icosavax","amount2":0.10000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.10000000000000001,"dosageForm":"Intramuscular Injection","sponsorNew":"Icosavax \/ RA Capital Management","highestDevelopmentStatusID":"4","companyTruncated":"Icosavax \/ RA Capital Management"},{"orgOrder":0,"company":"Icosavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"IVX-121","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Icosavax","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Icosavax \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Icosavax \/ Not Applicable"},{"orgOrder":0,"company":"Icosavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"IVX-411","moa":"SARS-CoV-2 virus protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Icosavax","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Icosavax \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Icosavax \/ Not Applicable"},{"orgOrder":0,"company":"Icosavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"IVX-121","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Icosavax","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Icosavax \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Icosavax \/ Not Applicable"},{"orgOrder":0,"company":"Icosavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"IVX-121","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Icosavax","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Icosavax \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Icosavax \/ Not Applicable"},{"orgOrder":0,"company":"Icosavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"IVX-121","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Icosavax","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Icosavax \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Icosavax \/ Not Applicable"},{"orgOrder":0,"company":"Icosavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"IVX-121","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Icosavax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Icosavax \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Icosavax \/ Not Applicable"},{"orgOrder":0,"company":"Icosavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"IVX-121","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Icosavax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Icosavax \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Icosavax \/ Not Applicable"},{"orgOrder":0,"company":"Icosavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"IVX-121","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Icosavax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Icosavax \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Icosavax \/ Not Applicable"},{"orgOrder":0,"company":"Icosavax","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2023","type":"Acquisition","leadProduct":"IVX-A12","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Icosavax","amount2":1.1000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":1.1000000000000001,"dosageForm":"Injection","sponsorNew":"Icosavax \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Icosavax \/ AstraZeneca"},{"orgOrder":0,"company":"Icosavax","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2024","type":"Acquisition","leadProduct":"IVX-A12","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Icosavax","amount2":1.1000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":1.1000000000000001,"dosageForm":"Injection","sponsorNew":"Icosavax \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Icosavax \/ AstraZeneca"},{"orgOrder":0,"company":"Icosavax","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"IVX-A12","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Icosavax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Icosavax \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Icosavax \/ AstraZeneca"},{"orgOrder":0,"company":"Icosavax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"IVX-121","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Icosavax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Icosavax \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Icosavax \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Icosavax

    Menu

    Icosavax

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Icosavax

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Icosavax

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IVX-A12

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : AstraZeneca

                            Deal Size : $1,100.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Acquisition of Icosavax Completed

                            Details : AstraZeneca acquires Icosavax’s IVX-A12, a combination protein vaccine for RSV and human metapneumovirus, targeting older adults.

                            Brand Name : IVX-A12

                            Molecule Type : Vaccine

                            Upfront Cash : $1,100.0 million

                            February 19, 2024

                            Lead Product(s) : IVX-A12

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : AstraZeneca

                            Deal Size : $1,100.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Icosavax

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Icosavax

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IVX-A12

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : AstraZeneca

                            Deal Size : $1,100.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Icosavax, Inc. Announces Agreement to be Acquired by AstraZeneca

                            Details : Through the acquisition of Icosavax, AstraZeneca gains access to IVX-A12, a combination virus like particle (VLP) vaccine candidate targeting both respiratory syncytial virus (RSV) and human metapneumovirus (hMPV).

                            Brand Name : IVX-A12

                            Molecule Type : Vaccine

                            Upfront Cash : $1,100.0 million

                            December 12, 2023

                            Lead Product(s) : IVX-A12

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : AstraZeneca

                            Deal Size : $1,100.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Icosavax

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Icosavax

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IVX-A12

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : AstraZeneca

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Icosavax Announces Positive Topline Interim Phase 2 Results for Combination VLP Vaccine Candidate IVX-A12 Agai...

                            Details : IVX-A12 is a combination virus like particle (VLP) vaccine candidate targeting both respiratory syncytial virus (RSV) and human metapneumovirus (hMPV). It is under phase 2 clinical development.

                            Brand Name : IVX-A12

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            December 12, 2023

                            Lead Product(s) : IVX-A12

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : AstraZeneca

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Icosavax

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Icosavax

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IVX-121,IVX-241

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Icosavax Announces Positive Topline Interim Phase 2 Results for Combination VLP Vaccine Candidate IVX-A12 Agai...

                            Details : IVX-A12 (IVX-121, IVX-241) is a vaccine drug candidate, which is being evaluated for the treatment of patients with respiratory syncytial virus infection in adults.

                            Brand Name : IVX-A12

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            December 12, 2023

                            Lead Product(s) : IVX-121,IVX-241

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Icosavax

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Icosavax

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IVX-121

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Icosavax Reports Positive 12-Month Durability Data for VLP Vaccine Candidate IVX-121 Against RSV and Initial E...

                            Details : IVX-A12 is a potential first-in-class combination vaccine candidate containing VLPs that incorporate stabilized prefusion F proteins from RSV and hMPV viruses.

                            Brand Name : IVX-121

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            August 08, 2023

                            Lead Product(s) : IVX-121

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Icosavax

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Icosavax

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IVX-121,IVX-241

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Icosavax Initiates Phase 2 Trial of IVX-A12 Against RSV and hMPV in Older Adults

                            Details : IVX-A12 is a combination bivalent vaccine candidate against both respiratory syncytial virus and human metapneumovirus. IVX-A12 is comprised of IVX-121, Icosavax’s RSV prefusion F protein VLP and IVX-241, Icosavax’s hMPV prefusion F protein VLP vacci...

                            Brand Name : IVX-A12

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            June 20, 2023

                            Lead Product(s) : IVX-121,IVX-241

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Icosavax

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Icosavax

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IVX-121,IVX-241

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Icosavax Announces Positive Topline Interim Phase 1 Results for Bivalent VLP Vaccine Candidate IVX-A12 Against...

                            Details : IVX-A12 is a combination bivalent vaccine candidate against both respiratory syncytial virus and human metapneumovirus. IVX-A12 is comprised of IVX-121, Icosavax’s RSV prefusion F protein VLP and IVX-241, Icosavax’s hMPV prefusion F protein VLP vacci...

                            Brand Name : IVX-A12

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            May 22, 2023

                            Lead Product(s) : IVX-121,IVX-241

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Icosavax

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Icosavax

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IVX-121,IVX-241

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Icosavax Granted FDA Fast Track Designation for IVX-A12

                            Details : IVX-A12 is a combination bivalent vaccine candidate against both respiratory syncytial virus and human metapneumovirus. IVX-A12 is comprised of IVX-121, Icosavax’s RSV prefusion F protein VLP and IVX-241, Icosavax’s hMPV prefusion F protein VLP vacci...

                            Brand Name : IVX-A12

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            February 21, 2023

                            Lead Product(s) : IVX-121,IVX-241

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Icosavax

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Icosavax

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IVX-121

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Icosavax Reports Positive Durability Data for VLP Vaccine Candidate IVX-121 Against RSV at Six-Month Timepoint

                            Details : In new data from Phase 1/1b study, IVX-121 showed sustained immunologic response at six months; geometric mean titers (GMT) against RSV-A through day 180 persisting at 64-98% of the GMTs at day 28 in older adults.

                            Brand Name : IVX-121

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            December 13, 2022

                            Lead Product(s) : IVX-121

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Icosavax

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Icosavax

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IVX-121,IVX-241

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Icosavax Initiates Phase 1 Trial of IVX-A12 Against RSV and hMPV in Older Adults

                            Details : IVX-A12 is comprised of IVX-121, Icosavax’s RSV prefusion F protein VLP vaccine candidate, and IVX-241, Icosavax’s hMPV prefusion F protein VLP vaccine candidate.

                            Brand Name : IVX-A12

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            October 04, 2022

                            Lead Product(s) : IVX-121,IVX-241

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth